Cystic fibrosis is an inherited condition that causes the body to make unusually thick, sticky mucus that clogs the lungs and digestive system and damages other organs over time. For decades it was a disease of childhood, but that story has changed dramatically: with newborn screening, specialized care, and a new generation of medicines that target the root genetic defect, a baby born with cystic fibrosis in the United States today has a median predicted survival of around 66 years. This guide explains what cystic fibrosis is, the symptoms across the body, how the sweat test and genetic testing confirm it, the treatments transforming care including CFTR modulators, and the latest research.
What is cystic fibrosis?
Cystic fibrosis is caused by faults in a gene called CFTR, which provides instructions for a protein that moves salt and water in and out of cells. When that protein is missing or does not work, the balance of salt and water at the surface of many organs goes wrong, and secretions that should be thin and slippery become thick and sticky. In the lungs this mucus traps bacteria and leads to repeated infections and lung damage, and in the digestive system it blocks the ducts of the pancreas so that enzymes cannot reach the intestine to digest food.
About 35,000 people in the United States live with cystic fibrosis, and it is most common in people of Northern and Central European ancestry. Because it affects several organ systems, it is best managed by a specialized care team. There is no cure yet, but treatment has advanced so far that the outlook and quality of life for people with cystic fibrosis have improved beyond what once seemed possible.
Symptoms of cystic fibrosis
Cystic fibrosis affects multiple body systems, and the mix and severity of symptoms vary from person to person. One classic sign parents may notice is that a baby’s skin tastes salty, a direct result of the salt imbalance in sweat. The main areas affected are summarized below.
| Body system | Common symptoms |
|---|---|
| Lungs and sinuses | Persistent cough with thick mucus, wheezing, recurrent lung and sinus infections, and nasal polyps |
| Digestive system | Poor weight gain and growth, greasy or foul-smelling stools, and blocked intestines in newborns |
| Whole body | Salty-tasting skin, fatigue, and, over time, complications such as diabetes and bone thinning |
| Reproductive system | Reduced fertility, with most men affected by the condition being infertile |
Over the years, cystic fibrosis can lead to complications including cystic fibrosis-related diabetes, which affects roughly half of adults with the condition, along with liver disease, weakened bones, and progressive lung damage called bronchiectasis. Respiratory failure remains the most serious long-term risk, which is why protecting lung function is central to care.
What causes cystic fibrosis?
Cystic fibrosis is caused by mutations in the CFTR gene, and it is inherited in an autosomal recessive pattern. That means a child must inherit one altered copy of the gene from each parent to have the disease; a child who inherits only one altered copy is a carrier who usually has no symptoms but can pass the gene on. Many carriers do not know they carry it, which is why cystic fibrosis can appear in families with no prior history.
More than a thousand CFTR mutations have been identified, but one, called F508del, is by far the most common. The specific mutations a person carries matter more than ever, because several newer treatments only work for particular genetic changes. Carrier screening before or during pregnancy can tell prospective parents whether they carry a CFTR mutation and help them understand the chance of having a child with cystic fibrosis.
How cystic fibrosis is diagnosed
Most cases in the United States are now identified through newborn screening, which tests a heel-stick blood sample for a marker called immunoreactive trypsinogen. A high level prompts follow-up testing, and every state screens newborns for cystic fibrosis. The diagnosis is then confirmed with the sweat chloride test, the long-standing gold standard, which measures the amount of chloride in sweat after a painless procedure that stimulates a small patch of skin.
| Sweat chloride result | What it suggests |
|---|---|
| 60 mmol/L or higher | Cystic fibrosis is likely; considered diagnostic |
| 30 to 59 mmol/L | Intermediate; further testing is needed |
| 29 mmol/L or lower | Cystic fibrosis is unlikely |
Genetic testing then identifies the exact CFTR mutations, which confirms the diagnosis in borderline cases, supports family counseling, and determines eligibility for specific modulator drugs. Because the disease revolves around chloride handling, it helps to understand what a chloride blood test measures, the same electrolyte that the sweat test evaluates. Learning how to read the flags and reference ranges on a lab report can make these results easier to interpret alongside your care team.
Treatment options for cystic fibrosis
Cystic fibrosis care has two goals: keep the airways clear and infection-free, and support digestion and nutrition. Daily airway clearance techniques and chest physiotherapy loosen and move mucus, inhaled medicines thin secretions and open airways, and inhaled or oral antibiotics treat and prevent lung infections. Because thick mucus blocks pancreatic enzymes, most people take enzyme capsules with meals and supplement the fat-soluble vitamins A, D, E, and K that are otherwise poorly absorbed. Monitoring levels such as the vitamin D level on a blood test is part of keeping nutrition on track.
The biggest change in modern care is a class of drugs called CFTR modulators, which help the faulty CFTR protein work better rather than just treating symptoms. These medicines have improved lung function, reduced flare-ups, and boosted nutrition for people with eligible mutations, and their approvals have steadily expanded to younger children and additional genetic variants. For advanced lung disease, lung transplantation remains an option. Because many people with cystic fibrosis develop cystic fibrosis-related diabetes, care also includes blood sugar monitoring, and understanding what a fasting glucose test shows helps families catch that complication early.
Living with cystic fibrosis and long-term outlook
Living well with cystic fibrosis means a consistent daily routine of airway clearance, medications, enzymes, and nutrition, along with regular visits to a specialized care center that monitors lung function, growth, blood sugar, liver health, and bone density. Staying current with vaccinations and treating infections promptly protects the lungs, and physical activity supports both lung function and overall health.
The outlook has improved remarkably. Better nutrition, early diagnosis through newborn screening, and especially CFTR modulator therapy have pushed median predicted survival into the sixties for children born today, and many adults with cystic fibrosis now work, travel, and raise families. Ongoing complications such as diabetes and bone thinning are managed proactively as part of lifelong care.
Latest scientific advances in cystic fibrosis research
The story of recent cystic fibrosis research is largely the story of CFTR modulators reaching more people and working in the real world. According to PubMed-indexed research, a 2025 trial in The Lancet Respiratory Medicine studied a newer once-daily modulator combination in children aged 6 to 11 and found it was safe, maintained lung function, and further improved CFTR activity, with nearly all children reaching sweat chloride levels below the diagnostic threshold (Hoppe et al., 2025). What this means for you: a simpler once-daily option is proving effective in school-age children, part of a steady push toward earlier and more convenient treatment.
A pivotal 2023 trial in the American Journal of Respiratory and Critical Care Medicine tested the triple-combination modulator in children as young as 2 and reported large drops in sweat chloride and improved measures of lung health, providing the evidence behind expanding this therapy down to age 2 (Goralski et al., 2023). What this means for you: children can now start disease-modifying treatment earlier in life, when protecting the lungs and pancreas may matter most. A 2025 review in the Journal of Clinical Medicine pulled together 57 registry-based studies and found that the benefits seen in trials, including better lung function and fewer flare-ups and a reduced need for lung transplantation, hold up in everyday practice (Salvatore et al., 2025). What this means for you: the gains from modulator therapy are real at the population level, which is a major reason survival estimates keep rising.
Glossary of key cystic fibrosis terms
| Term | Definition |
|---|---|
| CFTR gene | The gene that controls salt and water movement; its mutations cause cystic fibrosis. |
| F508del | The most common CFTR mutation responsible for cystic fibrosis. |
| Autosomal recessive | An inheritance pattern needing one altered gene copy from each parent. |
| Sweat chloride test | The gold-standard test that measures chloride in sweat to diagnose cystic fibrosis. |
| Pancreatic insufficiency | When blocked pancreatic ducts keep digestive enzymes from reaching the gut. |
| CFTR modulator | A drug that helps the faulty CFTR protein work better. |
| Bronchiectasis | Permanent widening and damage of the airways from repeated infection. |
Frequently asked questions about cystic fibrosis
What is cystic fibrosis?
Cystic fibrosis is an inherited disease in which faulty CFTR proteins cause the body to make thick, sticky mucus that clogs the lungs and digestive system and damages other organs. It is a lifelong condition managed by a specialized care team, and treatment has improved the outlook dramatically.
What causes cystic fibrosis?
It is caused by mutations in the CFTR gene and is inherited in an autosomal recessive pattern, so a child must inherit an altered copy from each parent to have it. People with only one altered copy are carriers who usually have no symptoms. The most common mutation is called F508del.
What are the early signs and symptoms of cystic fibrosis?
Early signs can include salty-tasting skin, poor weight gain despite a good appetite, greasy or bulky stools, and a persistent cough or frequent lung infections. Because newborn screening now catches most cases early, many babies are identified before symptoms become obvious.
How is cystic fibrosis diagnosed?
Diagnosis usually begins with newborn screening that checks a blood marker, followed by the sweat chloride test, which is the gold standard, and genetic testing to identify the exact mutations. A sweat chloride level of 60 mmol/L or higher is considered diagnostic.
What is the life expectancy for someone with cystic fibrosis today?
The outlook has improved greatly. A child born with cystic fibrosis in the United States today has a median predicted survival of around 66 years, thanks to newborn screening, better nutrition and airway care, and CFTR modulator therapy. Many adults with cystic fibrosis live full, active lives.
What are CFTR modulators and who is eligible?
CFTR modulators are medicines that help the faulty CFTR protein work better, improving lung function and nutrition rather than only treating symptoms. Eligibility depends on a person’s specific CFTR mutations and age, and approvals have expanded over time to include younger children and more mutations.
Sources
- Centers for Disease Control and Prevention — About Cystic Fibrosis — CDC, 2024 — cdc.gov
- Mayo Clinic Staff — Cystic Fibrosis: Symptoms and Causes — Mayo Clinic Diseases & Conditions, 2024 — mayoclinic.org
- Cystic Fibrosis Foundation — Sweat Test — CF Foundation, 2024 — cff.org
- Hoppe JE, Kasi AS, et al. — Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE) — Lancet Respiratory Medicine, 2025 — doi.org/10.1016/S2213-2600(24)00407-7
- Goralski JL, Hoppe JE, et al. — Phase 3 Open-Label Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis — American Journal of Respiratory and Critical Care Medicine, 2023 — doi.org/10.1164/rccm.202301-0084OC
- Salvatore D, Pepe A — CFTR Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence — Journal of Clinical Medicine, 2025 — doi.org/10.3390/jcm14113978
Further reading
- Understand the electrolyte at the heart of the sweat test in this guide to the chloride blood test and what it measures.
- See why fat-soluble vitamin levels are watched closely in this guide to the vitamin D blood level.
- Learn how a common complication is caught in this guide to the fasting glucose test.
- Explore a related lung condition in this guide to the airway inflammation of chronic bronchitis.
- Build confidence reading test results with this guide to reference ranges, flags, and next steps on a lab report.
Understand your lab results with BloodSense
Cystic fibrosis touches many parts of a lab report, from the chloride measured in a sweat test to the fat-soluble vitamins and blood sugar that shape long-term nutrition and health. Whenever you receive results, seeing where each value sits against its reference range, and how the numbers connect, makes them far easier to act on. BloodSense translates a full lab report into plain language, showing what each marker means and helping you track changes over time instead of decoding one line at a time.
